COVID -19: Case report of assertive treatment in diabetic patients

COVID 19 is currently one of the most impacting factors in world society, both because of the ineffectiveness of pharmacological measures and because of socioeconomic inequality. Diabetes is one of the comorbidities that makes the body more vulnerable to the development of severe COVID-19. Diabetes does not increase the patient's risk of becoming infected with the new coronavirus, but it does increase the chances of complications from the infection. This study uses a descriptive and observational methodology of the assertive evolution of the COVID-19 case report. It is a descriptive, exploratory, non-invasive method, with mediated intervention, in a 42-year-old male patient, type 2 diabetic, undergoing pharmacological monitoring and in treatment of lichenoid pityriasis with 500mg tetracycline hydrochloride, on alternate days. During treatment for pityriasis lichenoid, the patient contracted the coronavirus, changing the antibiotic for daily use, resulting in the remission of symptoms after 3 days of medication. This new scenario opens the possibility for clinical and scientific research through randomized studies of the antibiotic tetracycline hydrochloride 500 mg, to investigate its action on the viral replication of the new coronavirus.